Searched for: subject%3A%22tumor%255C%2Bnecrosis%255C%2Bfactor%255C%2Breceptor%255C%2B1%22
(1 - 2 of 2)
Rieckmann, P. (author), Kruse, N. (author), Nagelkerken, L. (author), Beckmann, K. (author), Miller, D. (author), Polman, C. (author), Dahlke, F. (author), Toyka, K.V. (author), Hartung, H.P. (author), Stürzebecher, S. (author), TNO Preventie en Gezondheid (author)
Background: Subcutaneous IFNβ-1b (Betaferon®) is an established immunomodulatory treatment for relapsing remitting MS and active secondary progressive multiple sclerosis (SPMS). It modulates cytokine and adhesion molecule expression but long term in vivo effects of IFNβ-1b on the immune system are not known in multiple sclerosis. Objective: To...
article 2005
TNO Preventie en Gezondheid (author), Bayley, J.P. (author), Bakker, A.M. (author), Kaijzel, E.L. (author), Huizinga, T.W.J. (author), Verweij, C.L. (author)
Objective. To assess the role of polymorphisms of the tumour necrosis factor (TNF) receptors, TNF-RI (p55) and TNF-RII (p75) in the susceptibility to and severity of rheumatoid arthritis (RA) in Dutch patients. Methods. A total of 319 consecutive RA patients, and a cohort of 90 female RA patients with detailed 12-yr follow-up were genotyped for...
article 2003